Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy

Acta Radiologica

Volumn 56, Issue 11, 2015, Pages 1300-1307

  Etxano, Jon ^a   Insausti, Luis Pina ^a   Elizalde, Arlette ^a   López Vega, José Manuel ^b   Plazaola, Arrate ^c   Martínez, Purificación ^d  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c Instituto Oncológico   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

Author keywords

bevacizumab; Breast neoplasms; magnetic resonance imaging (MRI); neoadjuvant treatment; pharmacodynamic; pharmacokinetics

Indexed keywords

CHEMOTHERAPY; DISEASES; MEDICAL IMAGING; PATIENT TREATMENT; PHARMACODYNAMICS; PHARMACOKINETICS; TUMORS;

BEVACIZUMAB; BREAST NEOPLASM; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HIGH TEMPORAL RESOLUTION; LOCALLY ADVANCED BREAST CANCER; NEOADJUVANT CHEMOTHERAPIES; NEOADJUVANT TREATMENT; TUMOR MICROVASCULATURE;

MAGNETIC RESONANCE IMAGING;

BEVACIZUMAB; DOCETAXEL; DOXORUBICIN; GADOBUTROL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ORGANOMETALLIC COMPOUND;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; COLLOID CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHARMACODYNAMICS; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84954623598     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185114556098     Document Type: Article

References (28)

1. Smith RA, Duffy SW, Tabár L,. Breast cancer screening: the evolving evidence. Oncology (Williston Park) 2012; 26: 471-475, 479-481, 485-486.
2. Sanchez MJ, Payer T, De Angelis R, et al. CIBERESP Working Group. Cancer incidence and mortality in Spain: estimates and projections for the period 1981-2012. Ann Oncol 2010; 21: 30-36.
3. Álvaro-Meca A, Debón A, Gil Prieto R, et al. Breast cancer mortality in Spain: has it really declined for all age groups Public Health 2012; 126: 891-895.
4. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
5. Mackey JR, Kerbel RS, Gelmon KA, et al. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev 2012; 38: 673-688.
6. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-320.
7. Kruse V, Denys H, Van Den Broecke R, et al. The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most Springerplus 2013; 2: 202-202.
8. Martín M, Makhson A, Gligorov J, et al. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist 2012; 17: 469-475.
9. Pierga JY, Petit T, Delozier T, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012; 13: 375-384.
10. Gradishar WJ,. Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl) 2012; 6: 159-171.
11. Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-1857.
12. Marinovich ML, Sardanelli F, Ciatto S, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast 2012; 21: 669-677.
13. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14: 6580-6589.
14. Li X, Arlinghaus LR, Ayers GD, et al. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: Pilot study findings. Magn Reson Med 2014; 71: 1592-1602.
15. Breast. In: Edge SB, Byrd DR, Compton CC, et al. (eds). AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010:347-376.
16. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 12: 320-327.
17. Leach MO, Morgan B, Tofts PS, et al. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol 2012; 22: 1451-1464.
18. Tofts PS, Berkowitz B, Schnall MD,. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995; 33: 564-568.
19. Thukral A, Thomasson DM, Chow CK, et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 2007; 244: 727-735.
20. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-777.
21. Barnes SL, Whisenant JG, Loveless ME, et al. Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer. Magn Reson Med 2013; 69: 1721-1734.
22. Etxano J, García-Lallana Valbuena A, Antón Ibáñez I, et al. Evaluation of the reproducibility of a protocol for the pharmacokinetic study of breast tumors by dynamic magnetic resonance imaging. Radiologia 2014; DOI:10.1016/j.rx.2013.01.006.
23. Carmeliet P, Jain RK,. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
24. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
25. Yi B, Kang DK, Yoon D, et al. Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients Eur Radiol 2014; 24: 1089-1096.
26. Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006; 239: 361-374.
27. El Khouli RH, Macura KJ, Kamel IR, et al. 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis. Am J Roentgenol 2011; 197: 1498-1505.
28. Arjaans M, Oude Munnink TH, Oosting SF, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013; 73: 3347-3355.